BikajuMab

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameBikajuMab
Drug Alias NameBikajumab (Novelmed Therapeutics Inc)anti-inflammatory monoclonal antibody (NovelMed)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLeukocyte elastase inhibitorsComplement factor B inhibitorsTumor necrosis factor α inhibitors
TargetsComplement factor BLeukocyte elastaseTumor necrosis factor α
Therapy Area/IndicationsCardiovascular DiseasesPneumonia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovelMed Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovelMed Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCardiovascular DiseasesPneumonia

Other Information

ATC CodeN/A
Related LinksN/A